Morphic to Present at SVB Leerink Global Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company focused on oral integrin therapies, will participate in the virtual SVB Leerink Global Healthcare conference on February 16, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company focused on oral integrin therapies, will participate in the virtual SVB Leerink Global Healthcare conference on February 16, 2023. The event will feature a fireside chat scheduled for 8:40 AM ET. A live webcast will be available on the Investor section of Morphic's website, with an archived replay accessible following the conference. Morphic is developing treatments for serious chronic diseases such as autoimmune, cardiovascular, and metabolic diseases, leveraging its innovative MInT technology platform in collaboration with Janssen.
Details
News Market Reaction – MORF
The recorded move for MORF in the trading session of this news was +5.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the virtual SVB Leerink Global Healthcare conference including a hosted fireside chat.
Presentation Information
8:40 AM ET, Thursday February 16, 2023
Fireside Chat at the SVB Leerink Conference
A live webcast of the presentation will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaborations with Janssen using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.